China revolutionizes AI with Deepseek and now attacks medicine
China revolutionizes AI with Deepseek and now attacks medicine
China’s Deepseek caused a stir with his unexpected innovation at an unbeatable price. But this disruptive trend is not only limited to the big technology companies: it also takes place quietly in the pharmaceutical sector.
Akeso revolutionizes the biotech sector
In September, Akeso, a little-known Chinese biotech company, which was founded almost a decade ago, broke the industry with its new drug against lung cancer. Ivonescimab, the new medicine China found that the treatment of Keytruda, the blockbuster medicinal product from Merck, has exceeded more than $ 130 billion generated sales for the American giant that dominates the cancer treatment market.
superiority in the clinical study
The patients treated with Akeso’s new medication lived on average 11.1 months before their tumors began to grow again, compared to only 5.8 months for Keytruda, according to the clinical data that were presented at the World Conference for Lung Cancer, an important medical forum.
increasing share price and attention
Within a few days at the beginning of September, Summit Therapeutics's share price, Akeso’s US partners, doubled more than and reached a record high, as data from Refinitive show. The company had licensed the rights to market the new drug in North America and Europe.
China's role in the global pharmaceutical market
Although experts said that this was a turning point for Chinese pharmaceutical companies, this was hardly noticed outside the industry. All of this changed according to the achievements of Deepseek at the beginning of the year, which directed international attention to innovation potential in China - with growing global effects.
"I firmly believe that the Chinese biotech industry will play an important global role. And we will take part in more and more," said Michelle Xia, the CEO of Akeso, in an interview last month with Biotechtv .
an exciting moment for Akeso
In a message to CNN, Akeso said that it was an "incredibly exciting moment" to see his medication against Keytruda, the world's best -selling medication. "Akeso’s innovation results from a deep understanding of the disease biology and protein engineering, while we benefit from the fast development times and the abundance of first-class talent in China," it said.
Kommentare (0)